Innovative Anti-infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential, According to GBI Research

21 Jun 2012 • by Natalie Aster

The antibacterials market is large and well-established but still seeing good growth due to the increasing problem of nosocomial infections and the rise of drug-resistant bacteria. According to the report “Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential” by GBI Research, despite several patent expiries, including that of Levaquin, one of the highest selling antibacterials, the market is expected to reach $12.7 billion in 2017 with new therapies needed to tackle pathogens that have developed resistance to older antibacterials. While the development of new antibacterials is not currently a hugely dynamic area, targeting multi-drug resistant Tuberculosis and other indications will require innovative solutions.

Report Details:

Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential
Published: May, 2012
Pages: 145
Price: US$ 3.500,00

Another example of a high unmet need is in the treatment of Gram-negative bacteria. As they have a more complicated cell wall it is very difficult to develop antibacterials for them at present and most companies are focusing on the less risky Gram-positive bacteria instead. New innovations in the area of Gram-negative bacteria have the potential to become a key driver of the antibacterials market in the future.

More information can be found in the report “Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential” by GBI Research.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com